Crinetics Pharmaceuticals (CRNX) Citi's 2024 Global Healthcare Conference summary

Strategic focus and innovation

• Focused on endocrine systems and peptide hormone receptors, developing non-peptide, small molecule ligands to treat endocrine and related diseases.

• Pipeline includes a lead compound in registration and four new molecules entering IND-enabling work.

• Approach targets both unmet needs in established markets and innovative treatments for conditions lacking effective therapies.

• New platform of non-peptide drug conjugates (NDCs) aims to improve targeted delivery for neuroendocrine tumors and other cancers.

• NDCs leverage small molecule chemistry for better targeting, internalization, and manufacturing compared to antibody drug conjugates.

Pipeline highlights and clinical progress

• Lead NDC candidate is set for clinical trials early next year, targeting neuroendocrine tumors expressing somatostatin receptors.

• PTH antagonist for hyperparathyroidism is in IND-enabling work, with an IND expected next year.

• Polycystic kidney disease candidate leverages somatostatin receptor ligands to address cyclic AMP imbalance, with IND planned for next year.

• FDA guidance allows for preliminary approval in polycystic kidney disease based on kidney volume, with confirmatory post-marketing studies on kidney function.

Paltusotine and acromegaly

• Paltusotine offers an oral alternative to painful, monthly depot injections for acromegaly, aiming to improve patient experience and disease management.

• Two pivotal trials, Pathfinder One and Two, demonstrated efficacy in both maintenance and treatment settings, with strong symptom control.

• Commercial opportunity includes new patients, those struggling with injectables, and a large segment of untreated patients.

• Strategies are being developed to reach patients not currently receiving therapy, including outreach through patient communities and physicians.